-
Views
-
Cite
Cite
Monica Cesarini, Erika Angelucci, Tiziana Foglietta, Piero Vernia, Guillain–Barrè syndrome after treatment with human anti-tumor necrosis factorα (adalimumab) in a Crohn's disease patient: Case report and literature review, Journal of Crohn's and Colitis, Volume 5, Issue 6, December 2011, Pages 619–622, https://doi.org/10.1016/j.crohns.2011.06.010
- Share Icon Share
Abstract
Anti-tumor necrosis factor alpha antibodies have been used with increasing frequency despite the number of reported adverse effects. Further new information is still emerging. Here we report the case of a 71-years-old patient affected by Crohn's disease and HCV-positive who developed Guillain–Barrè syndrome after four injections of fully human anti-tumor necrosis factor alpha antibodies (adalimumab). Indication for the treatment was severe clinical recurrence of Crohn's disease following intestinal resection. Guillain–Barrè syndrome was treated by intravenous immunoglobulins, and methylprednisolone and plasmapheresis were started with a progressive partial resolution of neurological symptoms. To date, Crohn's disease was maintained in clinical remission with low dose steroid therapy.
Highlights: ► An increased risk for developing demyelinating diseases has been reported in IBD patients. ► This is the first case of GBS developing in a IBD patient following ADA use. ► Patients receiving TNF-α antagonists should be monitored for neurologic signs and symptoms suggestive of demyelinating disease.
- tumor necrosis factors
- guillain-barre syndrome
- immunoglobulins, intravenous
- bowel resection
- crohn's disease
- demyelinating diseases
- inflammatory bowel disease
- methylprednisolone
- necrosis
- neurologic manifestations
- plasmapheresis
- antibodies
- neoplasms
- antagonists
- hepatitis c virus
- adalimumab
- steroid therapy
- miller fisher syndrome
- disease remission